

**Press Release**

**THE BOARD OF DIRECTORS APPROVES THE ALLOCATION OF OPTIONS UNDER THE 2023-2028 STOCK OPTION PLAN**

**Viareggio, 26 May 2023 - Talea Group S.p.A.** – a company listed on the Euronext Growth Milan market of the Italian Stock Exchange, resulting from the rebranding of Farmaè S.p.A. and leader in the e-retailing of products for personal health and wellbeing and in media and digital transformation services for businesses (the "**Company**") - hereby announces that the Board of Directors resolved today to allocate the options of the 2023-2028 Stock Option Plan (the "**Stock Option Plan**") approved by the Shareholders' Meeting on 28 April 2023.

Specifically, the Board of Directors allocated 72,500 options to 13 beneficiaries among the executive directors, executives with strategic responsibilities, other employees and consultants of the Company and/or other subsidiary. The options grant the right to purchase, and possibly subscribe, shares of the Company at a ratio of 1 share for every 1 option exercised. The exercise of the options is subject to the achievement of the performance targets set forth in the regulations of the 2021-2023 Stock Option Plan and, in particular, referring to the EBITDA for the year 2023 as envisaged in the 2023-2025 business plan approved by the Board of Directors on 23 March. The exercise price, calculated on the basis of the provisions of the Stock Option Plan, was set at EUR 11.20.

Pursuant to Article 84-bis, paragraph five, of Consob Regulation No. 11971/1999 (the "**Issuers' Regulation**"), the beneficiaries of the option allocation are listed below:

- n. 5 directors of the Company, namely Riccardo Iacometti (who also indirectly controls the Company), Alberto Maglione, Giuseppe Cannarozzi, Vincenza Nicoletta Colucci and Marco Di Filippo (the latter also a director in the subsidiary Amica Farmacia S.r.l.);
- n. 1 director of the subsidiary Valnan S.r.l., namely Marco Maglione;
- n. 4 executives with strategic responsibilities of the Company;
- n. 2 other employees of the Company; and
- n. 1 collaborator of the Company.

For further details on the Stock Option Plan, please refer to the Regulation of the Stock Option Plan available in the section "Governance/Corporate Documents and Procedures/Corporate Documents" of the Company's website ([www.taleagroupspa.com](http://www.taleagroupspa.com)) and to the Information Document, already made available to the public pursuant to articles 114-bis of Legislative Decree no. 58 of 24 February 1998 (the "**TUF**", i.e. "Consolidated Law on Finance") and 84-bis, first paragraph, of the Issuers' Regulation, in the section "Governance/Shareholders' Meetings/2023" of the Company's website ([www.taleagroupspa.com](http://www.taleagroupspa.com)), which will be updated in compliance with the provisions of Article 84-bis, fifth paragraph, of the Issuers' Regulation.

\*\*\*

This press release is available in the Investor Relations section of the Company's website [www.taleagroupspa.com](http://www.taleagroupspa.com).

\*\*\*

Talea Group S.p.A., a company listed on the Euronext Growth Milan market of the Italian Stock Exchange and resulting from the rebranding of Farmaè S.p.A., is one of the leading digital groups in Europe in the Health, Wellness and Beauty multichannel macro-sector and in media and digital transformation services for businesses. Talea Group S.p.A. operates with a business model based on two revenue-generating areas: the Consumers Area, dedicated to e-retailing and currently featuring the brands Farmaè, Amicafarmacia, Farmaeurope, Sanort and Beautyè, and the Industrial Area, focusing on media services and digital transformation with Talea Media and

# TALEA GROUP

DIGITAL PEOPLE ORIENTED

Valnan Communications. The Group - which currently employs more than 240 professionals - places People and Companies at the centre of its values and actions aimed at satisfying their needs and desires, and bases its identity on digital culture and the ability to evolve business models and generate growth within the reference markets through innovative and sustainable solutions.

For further information:

## **Euronext Growth Advisor**

Alantra Capital Markets  
+39 02 63671601  
Stefano Bellavita  
[stefano.bellavita@alantra.com](mailto:stefano.bellavita@alantra.com)

## **Investor Relation**

Farmaè  
Investor Relations Officer  
Alberto Maglione  
+39 0584 1660552  
[ir@farmaegroup.it](mailto:ir@farmaegroup.it)

## **CDR Communication**

IR Advisor  
Vincenza Colucci  
Tel. +39 335 6909547  
[vincenza.colucci@cdr-communication.it](mailto:vincenza.colucci@cdr-communication.it)

## **Specialist**

MIT SIM S.p.A.  
+39 02 30561 276  
[trading-desk@mitsim.it](mailto:trading-desk@mitsim.it)

## **Media Relation**

SEC Newgate – 02.6249991 – [farmae@segrp.com](mailto:farmae@segrp.com)  
Daniele Pinosa – 335 7233872 – [daniele.pnosa@secnewgate.it](mailto:daniele.pnosa@secnewgate.it)  
Fabio Santilio – 339 8446521 – [fabio.santilio@secnewgate.it](mailto:fabio.santilio@secnewgate.it)  
Giorgia Cococcioni – 366 2363331 – [giorgia.cococcioni@secnewgate.it](mailto:giorgia.cococcioni@secnewgate.it)